Search

Displaying results 1491 - 1500 of 4588 in total
  1. Drug

    Oxethazaine

    go.drugbank.com/drugs/DB12532
    ApprovedWithdrawn

    [L1113] It is also in the list of approved derivatives of herbal products by the EMA.[L2816] … [A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.

  2. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  3. Drug

    Indium In-111 pentetate

    go.drugbank.com/drugs/DB09425
    Approved

    Decay of In-111 by electron capture allows for detection with a gamma camera for visualization of the brain and spinal column.

  4. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    [L43942,L42975] Chlormadinone acetate continues to be used in other countries due to its high contraceptive efficacy and tolerability.[A254422,L33974]

  5. Drug

    Carbon dioxide

    go.drugbank.com/drugs/DB09157
    ApprovedInvestigationalVet approved

    Medical Carbon Dioxide is a liquefied medicinal gas, supplied in cylinders filled to a high pressure. Medical Carbon Dioxide may be used in different situations, e.g.

  6. Drug

    Isopropamide

    go.drugbank.com/drugs/DB01625
    ApprovedVet approvedWithdrawn

    It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.

  7. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  8. Drug

    Sabatolimab

    go.drugbank.com/drugs/DB16322
    Investigational

    Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic

  9. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    [A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]

  10. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. … Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]